These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 25985938)

  • 41. Stalking the guardian of the genome: p53 in colorectal carcinogenesis.
    Ahnen DJ
    Am J Gastroenterol; 1996 Jan; 91(1):3-6. PubMed ID: 8561139
    [No Abstract]   [Full Text] [Related]  

  • 42. Regulation of telomerase and its hTERT messenger in colorectal cancer.
    Boldrini L; Faviana P; Gisfredi S; Donati V; Zucconi Y; Ursino S; Simi P; Baldinotti F; Berti P; Galleri D; Materazzi G; Basolo F; Miccoli P; Pingitore R; Fontanini G
    Oncol Rep; 2004 Feb; 11(2):395-400. PubMed ID: 14719074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic relevance of p53 mutation in colorectal carcinoma.
    Ofner D; Schmid KW P
    Gastroenterology; 1994 Nov; 107(5):1571-2. PubMed ID: 7926526
    [No Abstract]   [Full Text] [Related]  

  • 44. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer.
    Khan SA; Zeng Z; Shia J; Paty PB
    Pathol Oncol Res; 2017 Jul; 23(3):673-677. PubMed ID: 28025786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. p53 mutations in primary colorectal adenocarcinomas and liver metastases.
    Yao J; Goh HS; Smith DR
    Br J Surg; 1996 Sep; 83(9):1245-6. PubMed ID: 8983617
    [No Abstract]   [Full Text] [Related]  

  • 46. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.
    Carter A; Lin K; Sherrington PD; Atherton M; Pearson K; Douglas A; Burford A; Brito-Babapulle V; Matutes E; Catovsky D; Pettitt AR
    Leukemia; 2006 Apr; 20(4):737-40. PubMed ID: 16437137
    [No Abstract]   [Full Text] [Related]  

  • 48. Somatic mutations of the APC, KRAS, and TP53 genes in nonpolypoid colorectal adenomas.
    van Wyk R; Slezak P; Hayes VM; Buys CH; Kotze MJ; de Jong G; Rubio C; Dolk A; Jaramillo E; Koizumi K; Grobbelaar JJ
    Genes Chromosomes Cancer; 2000 Feb; 27(2):202-8. PubMed ID: 10612810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is there a role for routine p53 testing in colorectal cancer?
    Hoff PM
    J Clin Oncol; 2005 Oct; 23(30):7395-6. PubMed ID: 16186590
    [No Abstract]   [Full Text] [Related]  

  • 50. Aberrations of BUBR1 and TP53 gene mutually associated with chromosomal instability in human colorectal cancer.
    Zhao Y; Ando K; Oki E; Ikawa-Yoshida A; Ida S; Kimura Y; Saeki H; Kitao H; Morita M; Maehara Y
    Anticancer Res; 2014 Oct; 34(10):5421-7. PubMed ID: 25275037
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Invasiveness and metastasis in colorectal cancer: P53 gene alteration associated with hepatic metastasis].
    Fushida S; Miwa K
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():107-10. PubMed ID: 14574865
    [No Abstract]   [Full Text] [Related]  

  • 52. The different radiation response and radiation-induced bystander effects in colorectal carcinoma cells differing in p53 status.
    Widel M; Lalik A; Krzywon A; Poleszczuk J; Fujarewicz K; Rzeszowska-Wolny J
    Mutat Res; 2015 Aug; 778():61-70. PubMed ID: 26099456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
    Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
    Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors.
    Favis R; Huang J; Gerry NP; Culliford A; Paty P; Soussi T; Barany F
    Hum Mutat; 2004 Jul; 24(1):63-75. PubMed ID: 15221790
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Changes in the TP53 tumor suppressor gene in malignant transformation of Barrett esophagus].
    Ferec C; Audrezet MP; Mercier B; Robaszkiewicz M
    Gastroenterol Clin Biol; 1994; 18(1 Pt 2):D46-51. PubMed ID: 8013783
    [No Abstract]   [Full Text] [Related]  

  • 57. Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer.
    Tang NP; Wu YM; Wang B; Ma J
    Eur J Surg Oncol; 2010 May; 36(5):431-8. PubMed ID: 20363586
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.
    Al-Tassan NA; Whiffin N; Hosking FJ; Palles C; Farrington SM; Dobbins SE; Harris R; Gorman M; Tenesa A; Meyer BF; Wakil SM; Kinnersley B; Campbell H; Martin L; Smith CG; Idziaszczyk S; Barclay E; Maughan TS; Kaplan R; Kerr R; Kerr D; Buchanan DD; Win AK; Hopper J; Jenkins M; Lindor NM; Newcomb PA; Gallinger S; Conti D; Schumacher F; Casey G; Dunlop MG; Tomlinson IP; Cheadle JP; Houlston RS
    Sci Rep; 2015 May; 5():10442. PubMed ID: 25990418
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.
    Xu J; Liu Y; Li Y; Wang H; Stewart S; Van der Jeught K; Agarwal P; Zhang Y; Liu S; Zhao G; Wan J; Lu X; He X
    Nat Nanotechnol; 2019 Apr; 14(4):388-397. PubMed ID: 30804480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II.
    Li Y; Liu Y; Xu H; Jiang G; Van der Jeught K; Fang Y; Zhou Z; Zhang L; Frieden M; Wang L; Luo Z; Radovich M; Schneider BP; Deng Y; Liu Y; Huang K; He B; Wang J; He X; Zhang X; Ji G; Lu X
    Nat Commun; 2018 Oct; 9(1):4394. PubMed ID: 30349055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.